http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 26 Feb 2026 09:01:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+26/26065701.html si-local-file:///var/storage/secattach/20260226/26065701.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+26/26065701.html Thu, 26 Feb 2026 09:01:00 -0500 CLGN O.06052736 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+26/26065701.html si-local-file:///var/storage/secattach/20260226/26065701.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+26/26065701.html Thu, 26 Feb 2026 09:01:00 -0500 CLGN O.06052736 http://www.streetinsider.com/Corporate+News/CollPlant+secures+Korean+patent+for+photocurable+dermal+filler+technology/26064876.html <p>CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) announced that the Korean Patent Office has allowed a patent application covering its photocurable dermal filler technology. The patent protects a polymerizable solution for tissue augmentation that is injected into sub-epidermal tissue and then polymerized using external light activation.</p><p>The patent covers CollPlant's photocuring platform for dermal fillers, which uses the company's recombinant human collagen technology. The polymerizable formulation includes chemically modified recombinant human collagen and additional components, including a hyaluronic acid-based filler. The solution is designed to flow through surgical needles of at least 27-gauge and allows for post-injection contour adjustment before, during, or after http://www.streetinsider.com/Corporate+News/CollPlant+secures+Korean+patent+for+photocurable+dermal+filler+technology/26064876.html Thu, 26 Feb 2026 08:03:40 -0500 CLGN http://www.streetinsider.com/Press+Releases/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html <div class="xn-content"> <ul type="disc"><li><b><i>Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product</i></b> <b><i>Candidate</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.collplant.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant Biotechnologies</span></a> (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary  recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5229"><p><a target="_blank" href="https://mma.prnewswire.com/media/2921182/CollPlant.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2921182/CollPlant.jpg" title="Intellectual Property Rights Secured in One of http://www.streetinsider.com/Press+Releases/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html Thu, 26 Feb 2026 08:00:00 -0500 CLGN O.06052736 http://www.streetinsider.com/Press+Releases/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html <div class="xn-content"> <ul type="disc"><li><b><i>Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product</i></b> <b><i>Candidate</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.collplant.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant Biotechnologies</span></a> (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary  recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5229"><p><a target="_blank" href="https://mma.prnewswire.com/media/2921182/CollPlant.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2921182/CollPlant.jpg" title="Intellectual Property Rights Secured in One of http://www.streetinsider.com/Press+Releases/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html Thu, 26 Feb 2026 08:00:00 -0500 CLGN O.06052736 http://www.streetinsider.com/PRNewswire/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html <div class="xn-content"> <ul type="disc"><li><b><i>Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product</i></b> <b><i>Candidate</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.collplant.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant Biotechnologies</span></a> (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary  recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5229"><p><a target="_blank" href="https://mma.prnewswire.com/media/2921182/CollPlant.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2921182/CollPlant.jpg" title="Intellectual Property Rights Secured in One of http://www.streetinsider.com/PRNewswire/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html Thu, 26 Feb 2026 08:00:00 -0500 CLGN O.06052736 http://www.streetinsider.com/PRNewswire/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html <div class="xn-content"> <ul type="disc"><li><b><i>Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product</i></b> <b><i>Candidate</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.collplant.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant Biotechnologies</span></a> (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary  recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market.</p><div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5229"><p><a target="_blank" href="https://mma.prnewswire.com/media/2921182/CollPlant.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2921182/CollPlant.jpg" title="Intellectual Property Rights Secured in One of http://www.streetinsider.com/PRNewswire/CollPlant+Biotechnologies+Announces+Korean+Patent+Allowance+Secured+for+its+Photocurable+Dermal+Filler/26064838.html Thu, 26 Feb 2026 08:00:00 -0500 CLGN O.06052736 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+23/26039247.html si-local-file:///var/storage/secattach/20260223/26039247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+23/26039247.html Mon, 23 Feb 2026 07:19:00 -0500 CLGN O.06052736 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+23/26039247.html si-local-file:///var/storage/secattach/20260223/26039247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+23/26039247.html Mon, 23 Feb 2026 07:19:00 -0500 CLGN O.06052736 http://www.streetinsider.com/Corporate+News/CollPlant+launches+BioFlex+bioink+kit+for+3D+bioprinting+applications/26039168.html <p>CollPlant (NASDAQ: CLGN) announced the launch of BioFlex, a ready-to-print bioink kit designed for Digital Light Processing 3D bioprinting applications. The Rehovot, Israel-based company disclosed the product launch in a press release.</p><p>BioFlex includes Collink.3D 50, a biodegradable polymer component, combined with proprietary photoactive agents optimized for high-resolution DLP printing. The kit is engineered to support the biofabrication of tissue models for drug discovery and the development of engineered tissues and transplantable organs.</p><p>The system allows users to generate customized bioinks with tunable mechanical properties by following BioFlex formulation and printing guidelines. The ready-to-print format eliminates the need for extensive component screening http://www.streetinsider.com/Corporate+News/CollPlant+launches+BioFlex+bioink+kit+for+3D+bioprinting+applications/26039168.html Mon, 23 Feb 2026 07:02:22 -0500 CLGN http://www.streetinsider.com/Hot+Corp.+News/CollPlant+launches+BioFlex+bioink+kit+for+3D+bioprinting+applications/26039168.html <p>CollPlant (NASDAQ: CLGN) announced the launch of BioFlex, a ready-to-print bioink kit designed for Digital Light Processing 3D bioprinting applications. The Rehovot, Israel-based company disclosed the product launch in a press release.</p><p>BioFlex includes Collink.3D 50, a biodegradable polymer component, combined with proprietary photoactive agents optimized for high-resolution DLP printing. The kit is engineered to support the biofabrication of tissue models for drug discovery and the development of engineered tissues and transplantable organs.</p><p>The system allows users to generate customized bioinks with tunable mechanical properties by following BioFlex formulation and printing guidelines. The ready-to-print format eliminates the need for extensive component screening http://www.streetinsider.com/Hot+Corp.+News/CollPlant+launches+BioFlex+bioink+kit+for+3D+bioprinting+applications/26039168.html Mon, 23 Feb 2026 07:02:22 -0500 CLGN http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html <div class="xn-content"> <ul type="disc"><li><b><i>BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance</i></b></li><li><b><i>BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 23, 2026</chron></span> /PRNewswire/ -- <b><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant</span> </b>(NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/CollPlant+Elevates+rhCollagen+3D+Bioprinting+Portfolio+with+Launch+of+Ready-to-Print+BioFlex/26039076.html Mon, 23 Feb 2026 07:00:00 -0500 CLGN CPT CPT.MU O.06052736 http://www.streetinsider.com/SEC+Filings/Form++D++++++++++CollPlant+Biotechnologie+++++++++++++/26006630.html si-local-file:///var/storage/secattach/20260217/26006630.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++CollPlant+Biotechnologie+++++++++++++/26006630.html Tue, 17 Feb 2026 08:01:00 -0500 CLGN O.06052736 http://www.streetinsider.com/SEC+Filings/Form++D++++++++++CollPlant+Biotechnologie+++++++++++++/26006630.html si-local-file:///var/storage/secattach/20260217/26006630.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++CollPlant+Biotechnologie+++++++++++++/26006630.html Tue, 17 Feb 2026 08:01:00 -0500 CLGN O.06052736 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+17/26005967.html si-local-file:///var/storage/secattach/20260217/26005967.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+17/26005967.html Tue, 17 Feb 2026 07:14:00 -0500 CLGN O.06052736 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+17/26005967.html si-local-file:///var/storage/secattach/20260217/26005967.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CollPlant+Biotechnologie++For%3A+Feb+17/26005967.html Tue, 17 Feb 2026 07:14:00 -0500 CLGN O.06052736 http://www.streetinsider.com/Press+Releases/CollPlant+Targets+New+Aesthetic+Market+Driven+by+GLP-1+Weight-Loss+Treatments/26005707.html <div class="xn-content"> <p><i>Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to <span>GLP-1</span> weight-loss therapies</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 17, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.collplant.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant Biotechnologies</span></a> (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with <span>GLP-1</span> therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/CollPlant+Targets+New+Aesthetic+Market+Driven+by+GLP-1+Weight-Loss+Treatments/26005707.html Tue, 17 Feb 2026 07:00:00 -0500 CLGN CPT CPT O.06052736 http://www.streetinsider.com/Press+Releases/CollPlant+Targets+New+Aesthetic+Market+Driven+by+GLP-1+Weight-Loss+Treatments/26005707.html <div class="xn-content"> <p><i>Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to <span>GLP-1</span> weight-loss therapies</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 17, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.collplant.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:CLGN" idsrc="xmltag.org" >CollPlant Biotechnologies</span></a> (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with <span>GLP-1</span> therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/CollPlant+Targets+New+Aesthetic+Market+Driven+by+GLP-1+Weight-Loss+Treatments/26005707.html Tue, 17 Feb 2026 07:00:00 -0500 CLGN CPT CPT O.06052736